AI-generated research brief — verify at source
Self-Sampling HPV Testing Alongside Clinician Sampling Significantly Boosts Cervical Screening Uptake in Singapore
Offering self-sampling HPV DNA testing as an option alongside standard clinician sampling increased cervical cancer screening uptake by nearly 14 percentage points and more than tripled the rate of high-risk HPV detection compared with clinician sampling alone (absolute difference in HPV detection 2.8%, 95% CI 0.8–4.8; absolute difference in uptake 13.8%, 95% CI 6.0–21.4). Both effects were statistically robust, suggesting that expanding sample-collection options in primary care can meaningfully improve screening participation and pathogen identification.
What Was Studied
This trial examined whether offering women the choice of self-collected HPV DNA samples — in addition to the standard clinician-collected option — would increase screening uptake and improve detection of high-risk HPV strains compared with clinician sampling alone. The primary outcome was high-risk HPV DNA detection; screening uptake served as a key secondary endpoint. The rationale was that barriers to clinician-based collection may suppress participation, and providing an alternative route could reach women who would otherwise decline.
How It Was Studied
This was a pragmatic, two-arm randomised controlled trial using a Zelen design, conducted across NHG Polyclinics in Singapore between August 2024 and February 2025 — a follow-up window of approximately six months. Women aged 30 to 69 years who were due for cervical cancer screening were randomly assigned in a 1:1 ratio to either the intervention arm (offered a choice between clinician sampling followed by self-sampling) or usual care (clinician sampling only). Of 650 women randomised, 640 were included in the final analysis, with 320 per arm. Subgroup analyses examined outcomes by prior screening history, and multivariable modelling identified factors associated with sampling-method choice.
What Was Observed
- High-risk HPV detection was more than ten times higher in the intervention arm: 3.1% of women in the intervention group tested positive for high-risk HPV compared with only 0.3% in the usual-care group — an absolute difference of 2.8 percentage points (95% CI 0.8–4.8; P < .001). This difference was largely attributable to the greater number of women who completed screening in the intervention arm.
- Screening uptake was substantially higher when self-sampling was offered: 56.6% of women in the intervention arm completed screening versus 42.8% in the usual-care arm, an absolute gain of 13.8 percentage points (95% CI 6.0–21.4; P < .001). Benefit was observed both among women with a regular prior screening history and those who had never been screened before.
- Self-sampling was the preferred method among those who screened in the intervention arm: Of participants in the intervention group who completed screening, 56.4% chose self-sampling over clinician collection, indicating that the option was actively embraced rather than merely tolerated.
- Educational attainment was independently associated with sampling choice: Women with lower educational attainment had reduced odds of choosing self-sampling compared with declining screening altogether, pointing to a socioeconomic gradient in how the self-sampling option was adopted.
Why This Matters
Singapore’s national cervical cancer screening programme currently includes only clinician-based sampling, and coverage rates remain suboptimal. This trial demonstrates that adding a self-sampling pathway within existing primary care infrastructure can meaningfully increase both participation and detection of high-risk HPV, without replacing clinician sampling. At the same time, the finding that lower educational attainment predicts lower self-sampling uptake signals that equitable access to this option cannot be assumed — targeted engagement strategies will be needed if self-sampling is to benefit all eligible women.
How to Read This Result
Although the trial is well-designed and shows clear short-term benefits, its six-month duration and single-system setting in Singapore limit the certainty with which these findings can be generalised to other healthcare contexts or taken as evidence of long-term clinical impact such as cancer incidence reduction.
Limitations
The study period spanned only six months, which is insufficient to evaluate downstream clinical outcomes such as colposcopy follow-through, treatment completion, or cervical cancer incidence. The trial was conducted within a single healthcare network in Singapore, which may restrict applicability to other health systems or populations with different screening infrastructure. Equity concerns are also evident: women with lower educational attainment were less likely to choose self-sampling, suggesting that simply offering the option does not guarantee equitable uptake without additional supportive interventions.